Page 24 - Study Design News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Business im john nelda milan in berlin thanks for joining us the company about describes itself as a platform for inspiration had its first trading day on the New York Stock Exchange pinterest thought stocks surged more than thirty percent in its debut its valuation has been put at twelve point seven billion dollars the digital fan board site dedicated to sharing pictures of food fashion and travel claims of more than two hundred fifty million monthly users its the second biggest u. S. I. P. O. This year after riding hailing out lift went public last month like a few of its unicorn peers howev...

Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.

Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response and two stable disease observations have occurred as of May 15,...

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...